New Phase Research Development

Knoxville, Tennessee 37923

1 studies enrolling now · 35 studies all time

What they study most

Asthma, Atherosclerotic Cardiovascular Disease, Bladder Pain Syndrome, COPD, Cardiovascular Disease, Chronic Lower Back Pain, Chronic Obstructive Pulmonary Disease, Chronic Pain, Contraception, Covid19, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Studies at this site

• A Study to Evaluate Solrikitug in Participants With COPD (ZION) — Recruiting now
• A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus — Completed
• A Study to Evaluate Solriktug in Adult Participants With Asthma — Running, not enrolling
• Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery — Completed
• Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive — Stopped early
• A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS) — Stopped early
• A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome — Stopped early
• Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease — Running, not enrolling
• Gan & Lee Insulin Glargine Target Type (1) Evaluating Research — Completed
• The Prevent Severe COVID-19 (PRESECO) Study — Completed
• A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine — Completed
• A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD — Completed
• A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD — Completed
• Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment — Completed
• Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients — Completed
• Gan & Lee Insulin Glargine Target Type (2) Evaluating Research — Completed
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk — Completed
• Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain — Completed
• Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes — Completed
• A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome — Completed
• A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) — Completed
• Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD — Completed
• Cardiovascular Inflammation Reduction Trial — Completed
• A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use — Completed
• Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4) — Completed
• Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes — Completed
• Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus — Completed
• Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus — Completed
• A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone — Completed